2025-07-16 15:10:17

AstraZeneca shares fell 1% after Anselamimab failed to hit its main goal in a late-stage clinical trial.
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
ASIA TECH WIRE

Grasp technology trends

Download